4 free views remaining today

hypomyelinating leukodystrophy 9

ICD-10 Codes

Related ICD-10:

Description

Hypomyelinating leukodystrophy-9 (HLD9) is a rare genetic disorder that affects the development and maintenance of the myelin sheath, which is the fatty covering that surrounds and protects nerve fibers in the brain and spinal cord.

Characteristics:

  • Delayed psychomotor development [1]
  • Spasticity, which is increased muscle tone leading to stiffness and rigidity [2][5][9]
  • Nystagmus, a condition characterized by involuntary eye movements [3][5]
  • Onset in the first year of life [3]

Other symptoms:

  • Mild ataxia, which is a lack of coordination and balance [5]
  • Dysarthria, which is a speech disorder characterized by difficulty articulating words [5]

HLD9 is an autosomal recessive neurologic disorder, meaning that it is inherited in an autosomal recessive pattern. This means that a person must inherit two copies of the mutated gene (one from each parent) to develop the condition.

Causes:

  • A mutation in the RARS gene [4][8]

Overall, HLD9 is a rare and complex genetic disorder that affects the development and maintenance of the myelin sheath, leading to various neurological symptoms.

Additional Characteristics

  • dysarthria
  • nystagmus
  • spasticity
  • mild ataxia
  • delayed psychomotor development
  • Hypomyelinating leukodystrophy-9

Signs and Symptoms

Signs and Symptoms of Hypomyelinating Leukodystrophies

Hypomyelinating leukodystrophies, a type of leukodystrophy, can manifest in various ways. Some common signs and symptoms include:

  • Seizures: Seizures are a frequent occurrence in individuals with hypomyelinating leukodystrophies [9].
  • Spasticity (muscle tightness): Muscle tightness or stiffness is another symptom that may be experienced by those affected by this condition [9].
  • Growth difficulties: Growth and developmental delays can also be observed in children with hypomyelinating leukodystrophies [9].
  • Bowel and bladder problems: Issues with bowel and bladder control, such as constipation or urinary incontinence, may arise due to the degeneration of myelin sheaths [9].
  • Pain: Pain can be a symptom experienced by individuals with hypomyelinating leukodystrophies, particularly in the muscles and joints [9].
  • Drooling: Excessive drooling is another sign that may be observed in children with this condition [9].
  • Teeth grinding: Teeth grinding or bruxism can also occur due to muscle tension [9].
  • Sleep difficulties: Sleep disturbances, such as insomnia or excessive daytime sleepiness, may be experienced by individuals with hypomyelinating leukodystrophies [9].

It's essential to note that the severity and progression of symptoms can vary greatly among individuals with hypomyelinating leukodystrophies.

Additional Symptoms

  • Teeth grinding
  • Seizures
  • Drooling
  • Spasticity (muscle tightness)
  • Growth difficulties
  • Bowel and bladder problems
  • Sleep difficulties
  • pain

Diagnostic Tests

Diagnostic Tests for Hypomyelinating Leukodystrophy 9 (HLD9)

Hypomyelinating leukodystrophy 9 (HLD9) is a rare genetic disorder that affects the development of myelin, the fatty substance that surrounds and protects nerve fibers. Diagnosing HLD9 can be challenging, but several diagnostic tests are available to help confirm the condition.

Targeted Mutation Analysis

  • Targeted mutation analysis involves sequencing specific exons or regions of the RARS1 gene to detect point mutations, small deletions, or other genetic abnormalities associated with HLD9 [4].
  • This test is typically performed on a blood sample and can provide a definitive diagnosis for individuals suspected of having HLD9.

Sequence Analysis

  • Sequence analysis involves examining the entire coding region of the RARS1 gene to detect any mutations or abnormalities that may be causing the condition [5].
  • This test can also be performed on a blood sample and is often used in conjunction with targeted mutation analysis to confirm the diagnosis.

Other Diagnostic Tests

  • A comprehensive general and neurological examination, including a thorough patient history, can help identify individuals who may have HLD9 [6].
  • Imaging studies, such as MRI scans, may show white matter involvement or other abnormalities that are consistent with HLD9 [8].

Genetic Panels

  • Some genetic panels, such as the Invitae Leukodystrophy and Genetic Leukoencephaly Panel, can be used to diagnose HLD9 by assessing multiple genes associated with leukodystrophies [7].
  • These panels may also include assessment of non-coding variants and the maternally inherited mitochondrial genome.

Citation

[4] - Targeted mutation analysis is a specific test that involves sequencing selected exons or regions of the RARS1 gene to detect point mutations, small deletions, or other genetic abnormalities associated with HLD9. [5] - Sequence analysis involves examining the entire coding region of the RARS1 gene to detect any mutations or abnormalities that may be causing the condition. [6] - A comprehensive general and neurological examination can help identify individuals who may have HLD9 by assessing their overall health and neurological function. [7] - The Invitae Leukodystrophy and Genetic Leukoencephaly Panel is a genetic panel that includes assessment of multiple genes associated with leukodystrophies, including the RARS1 gene. [8] - Imaging studies, such as MRI scans, may show white matter involvement or other abnormalities that are consistent with HLD9.

Additional Diagnostic Tests

  • Sequence Analysis
  • Targeted Mutation Analysis
  • Imaging Studies (MRI)
  • Comprehensive General and Neurological Examination
  • Genetic Panels (Invitae Leukodystrophy and Genetic Leukoencephaly Panel)

Treatment

Current Research on Drug Treatments for Hypomyelinating Leukodystrophy

Research has been ongoing to find effective drug treatments for hypomyelinating leukodystrophy, a rare genetic disorder. According to recent studies [9], there are active gene therapy clinical trials for metachromatic leukodystrophy, adrenoleukodystrophy, globoid cell leukodystrophy, and other types of leukodystrophies.

  • Gene therapy is being explored as a potential treatment option for hypomyelinating leukodystrophy [9].
  • Clinical trials are underway to test the safety and efficacy of gene therapy in treating various forms of leukodystrophy [9].

While these studies hold promise, it's essential to note that more research is needed to determine the effectiveness of drug treatments for hypomyelinating leukodystrophy.

References:

[9] by J Metovic · 2024 · Cited by 1 — Within the leukodystrophies, there are active gene therapy clinical trials for metachromatic leukodystrophy, adrenoleukodystrophy, globoid cell leukodystrophy, ...

Recommended Medications

  • Gene therapy
  • Clinical trials

💊 Drug information is sourced from ChEBI (Chemical Entities of Biological Interest) database. Always consult with a healthcare professional before starting any medication. Click on any medication name for detailed information.

Differential Diagnosis

Differential Diagnosis of Hypomyelinating Leukodystrophies

Hypomyelinating leukodystrophies (HLDs) are a group of rare genetic disorders characterized by the deficiency or absence of myelin in the brain. The differential diagnosis of HLDs is crucial for accurate identification and management of these conditions.

Other Hypomyelinating Leukodystrophies

In cases where there are no typical dental abnormalities, other hypomyelinating leukodystrophies should be considered in the differential diagnosis. These include:

  • Pelizaeus-Merzbacher disease (PMD): A rare genetic disorder characterized by the accumulation of a specific type of lipid in the brain, leading to demyelination and neurological symptoms.
  • Allan-Herndon-Dudley syndrome: A rare X-linked recessive disorder that affects myelin formation and leads to severe developmental delay, muscle weakness, and other systemic complications.

Antenatal Diagnosis

Prenatal diagnosis of HLDs is possible through genetic testing and can provide valuable information for families at risk. This includes:

  • Genetic counseling: Providing families with accurate information about the risks and implications of carrying a specific genetic mutation.
  • Amniocentesis: A prenatal test that involves analyzing amniotic fluid to detect genetic abnormalities.

Key Points

  • HLDs are rare genetic disorders characterized by myelin deficiency or absence in the brain.
  • Differential diagnosis is crucial for accurate identification and management of these conditions.
  • Other hypomyelinating leukodystrophies, such as PMD and Allan-Herndon-Dudley syndrome, should be considered in cases where there are no typical dental abnormalities.
  • Antenatal diagnosis through genetic testing can provide valuable information for families at risk.

References

[6] (Other hypomyelinating leukodystrophies) [6] (Antenatal diagnosis)

Additional Information

oboInOwl#hasOBONamespace
disease_ontology
oboInOwl#id
DOID:0060791
core#notation
DOID:0060791
oboInOwl#hasDbXref
ORDO:438114
IAO_0000115
A hypomyelinating leukodystrophy characterized by delayed psychomotor development, spasticity, and nystagmus starting in the first year of life that has_material_basis_in compound heterozygous mutation in the RARS gene on chromosome 5q34.
oboInOwl#hasExactSynonym
RARS-related autosomal recessive hypomyelinating leukodystrophy
rdf-schema#label
hypomyelinating leukodystrophy 9
rdf-schema#subClassOf
t345243
oboInOwl#inSubset
http://purl.obolibrary.org/obo/doid#DO_rare_slim
IDO_0000664
http://purl.obolibrary.org/obo/GENO_0000148
relatedICD
http://example.org/icd10/E75.2
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
rdf-schema#domain
https://w3id.org/def/predibionto#has_symptom_1754
owl#annotatedSource
t345677

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.